Publications by authors named "M Carmen Cairo"
Pediatric patients with recurrent metastatic neuroblastoma (NB) have a dismal 5-year survival. Novel therapeutic approaches are urgently needed. The melanoma cell adhesion molecule (MCAM/CD146/MUC18) is expressed in a variety of pediatric solid tumors, including NB, and constitutes a novel target for immunotherapy.
View Article and Find Full Text PDFArticle Synopsis
- Pediatric patients with recurrent Ewing sarcoma have low survival rates and show low activity of natural killer (NK) cells due to an immunosuppressive tumor environment, which necessitates new treatment strategies.
- Researchers engineered chimeric antigen receptor (CAR) NK cells targeting melanoma cell adhesion molecule (MCAM) and tested their effectiveness, both alone and combined with NKTR-255 and magrolimab (MAG), in attacking ES cells.
- Results indicated that the anti-MCAM CAR enhanced NK cell activity specifically against ES cells, reduced metastasis, and improved survival rates in mouse models, while NKTR-255 and MAG further boosted the antitumor effects of CAR-NK cells.
Article Synopsis
- Malignant peripheral nerve sheath tumors (MPNST) are tough to treat because they often come back after surgery and don't respond well to regular chemotherapy.
- A new treatment called oncolytic viroimmunotherapy, which uses viruses to help fight tumors, shows promise but doesn’t work for everyone, so more research is needed to improve it.
- In experiments, using specific drugs along with the oncolytic virus helped some mice live longer by boosting their immune response against the tumors, leading to less suppressive cells in the tumor area, though the tumors didn’t shrink.